London, UK, 3rd July 2025: PharmaVentures is pleased to announce the appointment of Samara Ferguson as Vice President to lead its Pricing and Market Access division, supporting companies in their sell-side, buy-side, and licensing due diligence and deal-making.
For over 20 years, Samara has held multiple roles in the pharmaceutical industry, giving her a unique insight and experience in market access, health economics and outcomes research. At GSK, Amgen, and UCB, Samara worked across multiple product portfolios, supporting value demonstration of assets in clinical development through to post-launch.
Samara’s consultancy experience also brings many years of insight across numerous therapy areas, where she rigorously pressure-tested market access and price potential, developed market access strategies, evidence generation plans, and bespoke real-world studies.
Samara has also supported rapid assessments of in-licensing opportunities to identify key areas of risk and opportunities and inform investment decision-making.
Dr Fintan Walton, Founder and CEO of PharmaVentures, said:” We are delighted to welcome Samara to the PharmaVentures team. Her 20+ extensive years of experience working for major pharma and advising numerous small to mid-sized pharma will be an enormous benefit to our clients who need high-quality pricing and market access support in due diligence and negotiating the right terms for their deals.”
Samara holds a MSc in Health Economics and Health Policy from the University of Birmingham.
For further information, please contact:
Rachel Hampstead
rachelh@pharmaventures.com
About PharmaVentures
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.
PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
PharmaVentures’ services include:
- M&A (divestments, mergers, acquisitions, and strategic transactions)
- Licensing (in and out licensing)
- Fundraising Support
- Strategy (commercialisation, deal strategy, due diligence, market entry)
- Valuations (licensing, M&A, and fundraising)
- Pricing and Market Access
NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.
For more details, visit https://www.pharmaventures.com